GlobeNewswire by notified

King Faisal Specialist Hospital and Research Centre Highlights its Space Biomedical Research Journey at the Global Health Exhibition

Share

RIYADH, Saudi Arabia, Oct. 29, 2023 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is presenting its pioneering journey and prospects in space biomedical research and its role in enhancing human health at the Global Health Exhibition, where KFSH&RC is also participating as a strategic healthcare partner.

At the Exhibition, KFSH&RC delves into its groundbreaking experience leading four research experiments in cell sciences in space. These experiments encompass testing the immune cell response to inflammation in space, monitoring the activity of thousands of genes in immune cells exposed to inflammation over time, and tracking the changes in the lifespan of ribonucleic acid (mRNA) between space and Earth. Additionally, the pavilion simulates the inflammatory response to drug treatment using an immune cell model to explore its potential applications for prevention and early treatment.

The aim of these research experiments, conducted in collaboration with the Saudi Space Authority, as part of the scientific mission of Saudi astronauts Rayyanah Barnawi and Ali Al-Qarni to the International Space Station (ISS), is to contribute to exploratory research and its applications in space medicine to enhance the safety of space explorers and utilize the knowledge gained for the benefit the patient community globally.

The scientific experiments lasted for four days and were overseen by the research team led by Dr. Khaled Saad Abu Khubrah, Head of the Department of Molecular Biomedicine and Research at KFSH&RC, along with Dr. Wijdan Al-Ahmadi from KFSH&RC and Dr. Edward Hattie from the BioServe Space Technologies Center in Colorado, USA.

KFSH&RC is actively pursuing further research in space biomedical science to gain a more comprehensive understanding of the effects of gravity deficiency and cosmic radiation on the human body. They aim to leverage the unique space environment, which provides opportunities for medical experiments that are not feasible on Earth. This includes studying how cells and tissues grow in microgravity conditions, potentially leading to groundbreaking discoveries in disease treatments and opening new avenues in space medicine.

KFSH&RC is globally renowned for its specialized healthcare services and its leadership in innovation. It stands as an advanced centre for medical research and education, aiming to advance medical technologies and raise the standard of healthcare worldwide through partnerships with prominent local, regional, and international institutions in clinical, research, and educational fields.

Contact information:
kfshrc@mcsaatchi.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/78eba5fa-19d6-437c-ab42-c9a09636e91e

https://www.globenewswire.com/NewsRoom/AttachmentNg/c30c198b-dd13-4d48-8b8c-6667eda49b45

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Tenaris Announces 2023 Fourth Quarter and Annual Results21.2.2024 22:27:52 CET | Press release

The financial and operational information contained in this press release is based on audited consolidated financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS Accounting Standards. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Free Cash Flow, Net cash / debt and Operating working capital days. See exhibit I for more details on these alternative performance measures. LUXEMBOURG, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) today announced its results for the fourth quarter and year ended December 31, 2023 with comparison to its results for the fourth quarter and year ended December 31, 2022. Summary of 2023 Fourth Quarter Results 4Q 20233Q 2023 4Q 2022 Net sales ($ million)3,4153,2385%3,620(6%)Operating income ($

Standard Lithium to Participate in Upcoming Industry Conferences21.2.2024 22:05:14 CET | Press release

VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced senior leadership participation in the following upcoming industry conferences: Event BMO 33rd Global Metals, Mining and Critical Minerals ConferenceDateFebruary 26 – 28, 2024PresentationRobert Mintak, CEO and Director, February 27 - 10:45 to 11:00am ETEvent BofA Global Agriculture and Materials Conference 2024DateFebruary 27 – 29, 2024PanelLithium Panel Discussion featuring Robert Mintak, CEO and Director, February 29 – 8:20 to 9:00am ETEvent 36th Annual Roth ConferenceDateMarch 17 – 19, 2024 Management will be hosting one-on-one meetings during the conferences. Interested investors should contact their BMO, Bank of America, or Roth representative or Standard Lithium Investor Relations at investors@standardlithium.com. About Standard Lithium Ltd. Standa

Lantronix Announces Percepxion™, Its New Cloud Software Platform for IoT Devices21.2.2024 22:05:00 CET | Press release

Percepxion™ comes pre-configured in Lantronix’s gateways, routers, trackers and switches to accelerate IoT edge device deployments IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global provider of compute and connectivity IoT solutions, today announced Percepxion™, its new Cloud IoT Edge Solutions platform. Percepxion is pre-configured into Lantronix’s award-winning IoT gateways, routers, trackers and switches to provide secure, comprehensive device lifecycle management. The Percepxion platform efficiently scales edge deployments from regional to global and is managed through an intuitive single pane of glass. “The Percepxion platform provides our customers with an easy-to-deploy IoT solution that comes pre-configured on our connect and compute products,” said Jacques Issa, vice president of Marketing at Lantronix Inc. “Percepxion’s multi-tenant feature enables a B2B solution, generating incremental revenue streams for our end customers.” Remote inst

Amaroq publishes a Supplementary Prospectus in connection with Fundraising21.2.2024 19:09:16 CET | Press release

TORONTO, ONTARIO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- ("Amaroq" or the "Corporation" or the "Company") Amaroq publishes a Supplementary Prospectus in connection with Fundraising TORONTO, ONTARIO – 21 February 2024 – Amaroq Minerals Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ), an independent mining company with a substantial land package of gold and strategic energy transition mineral assets in Southern Greenland, announces publication of a Supplementary Prospectus, consisting of a Supplement to the Registration Document dated 12 September 2023 and a Securities Note, along with a Summary, all dated 21 February 2024, related to fundraising, details of which were disclosed in announcements on 12 and 13 February 2024. The Supplementary Prospectus dated 21 February 2024, has been approved by the Financial Supervisory Authority of the Central Bank of Iceland. The Supplementary Prospectus which is written in English, has been published electronically to the company’s website https://www.amaroqminer

AMG Reports Record-Setting Earnings for the Full Year 202321.2.2024 18:04:58 CET | Press release

Amsterdam, 21 February 2024(Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) reported record-setting adjusted EBITDA $350 million in 2023, due largely to strong profitability in our lithium and vanadium businesses. Fourth quarter 2023 revenue was $367 million, a 6% decrease versus the fourth quarter of 2022. Fourth quarter 2023 adjusted EBITDA of $71 million decreased 32% compared to the fourth quarter of 2022. Cash from operating activities was $223 million in 2023, the highest in AMG’s history, and 33% higher than the $168 million in 2022. In 000’s US dollarsQ4 ‘23Q4 ‘22ChangeFY ‘23FY ‘22ChangeRevenue$367,235$390,004 (6%)$1,625,861$1,642,774 (1%)Adjusted EBITDA (1)71,142104,061 (32%)350,491342,550 2%Cash from operating activities44,70456,969 (22%)223,000167,567 33%Return on Capital Employed 26.3% 30.8% 26.3% 30.8% Note: (1) Adjusted EBITDA is defined as EBIT adjusted for depreciation and amortization. Dr. Heinz Schimmelbusch, Chairman of the M

HiddenA line styled icon from Orion Icon Library.Eye